Jaguar Health (NASDAQ:JAGX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Jaguar Health (NASDAQ:JAGXGet Rating) in a research note released on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Shares of NASDAQ:JAGX opened at $0.30 on Tuesday. Jaguar Health has a one year low of $0.27 and a one year high of $5.34. The company has a 50 day moving average of $0.39 and a 200-day moving average of $0.64. The company has a debt-to-equity ratio of 3.06, a current ratio of 1.49 and a quick ratio of 1.24. The stock has a market cap of $24.21 million, a price-to-earnings ratio of -0.24 and a beta of 1.83.

Jaguar Health (NASDAQ:JAGXGet Rating) last released its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.40) earnings per share for the quarter. Jaguar Health had a negative return on equity of 319.63% and a negative net margin of 1,023.99%. The firm had revenue of $2.63 million for the quarter. During the same quarter last year, the firm earned ($0.30) earnings per share. Equities research analysts anticipate that Jaguar Health will post -0.84 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. Buckingham Strategic Wealth LLC bought a new position in Jaguar Health during the 4th quarter worth approximately $33,000. Renaissance Technologies LLC bought a new position in Jaguar Health in the first quarter valued at approximately $1,079,000. Virtu Financial LLC lifted its stake in Jaguar Health by 76.1% in the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 99,073 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Jaguar Health by 507.3% in the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 141,796 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Jaguar Health by 153.3% in the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 33,148 shares in the last quarter. 11.91% of the stock is currently owned by institutional investors and hedge funds.

About Jaguar Health (Get Rating)

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Featured Stories

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.